Bone marrow mesenchymal stem cells reduce the antitumor activity of cytokine-induced killer/natural killer cells in K562 NOD/SCID mice

详细信息    查看全文

• 作者：1. Department of Pediatrics ; Sun Yat-Sen Memorial Hospital ; Sun Yat-Sen University ; Guangzhou ; People’s Republic of China2. Department of Hematology ; Guang Zhou Women and Children’s Medical Center ; Guangzhou ; 510120 China3. Biotherapy Center ; Sun Yat-Sen Memorial Hospital ; Sun Yat-Sen University ; Guangzhou ; People’s Republic of China4. Medical Research Center ; Sun Yat-Sen Memorial Hospital ; Sun Yat-Sen University ; Guangzhou ; People’s Republic of China5. Animal Experiment Center of Zhongshan School of Medicine ; Sun Yat-Sen University ; Guangzhou ; People’s Republic of China
• 关键词：Bone marrow mesenchymal stem cells – Cytokine ; induced killer cells – Immunosuppression – Umbilical cord blood – NOD/SCID mice
• 刊名：Annals of Hematology
• 出版年：2011
• 出版时间：August 2011
• 年：2011
• 卷：90
• 期：8
• 页码：873-885
• 全文大小：764.5 KB
• 参考文献：1. Bailey LC, Reilly AF, Rheingold SR (2009) Infections in pediatric patients with hematologic malignancies. Semin Hematol 46:313–324
  2. Giordano P, Molinari AC, Del Vecchio GC, Saracco P, Russo G, Altomare M et al (2010) Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia. Am J Hematol 85:325–330
  3. Schmiegelow K, Heyman M, Gustafsson G, Lausen B, Wesenberg F, Kristinsson J et al (2010) The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse. Leukemia 24:715–720
  4. Choi S, Henderson MJ, Kwan E, Beesley AH, Sutton R, Bahar AY et al (2007) Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone. Blood 110:632–639
  5. Konrad M, Metzler M, Panzer S, Ostreicher I, Peham M, Repp R et al (2003) Late relapses evolve from slow-responding subclones in t(12;21)-positive acute lymphoblastic leukemia: evidence for the persistence of a preleukemic clone. Blood 101:3635–3640
  6. Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R et al (2007) Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation:a phase I study. Haematologica 92:952–959
  7. Hongeng S, Petvises S, Worapongpaiboon S, Rerkamnuaychoke B, Pakakasama S, Jootar S (2003) Generation of CD3(+) CD56(+) cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells. Int J Hematol 77:175–177
  8. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL (1991) Use of a SCID mouse/human Lymphoma model to evalute cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174:139–149
  9. Sangiolo D, Mesiano G, Carnevale-Schianca F, Piacibello W, Aglietta M, Cignetti A (2009) Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation. Expert Opin Biol Ther 9:831–840
  10. Olioso P, Giancola R, Di Riti M, Contento A, Accorsi P, Iacone A (2009) Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours:a pilot clinical trial. Hematol Oncol 27:130–139
  11. Li Y, Huang SL, Zhang XC, Fang JP, Wu YF, Wei J et al (2008) The cytotoxicity of CIK/NK cells stimulated by K562-DC fusion vaccines in NOD/SCID mice model for human erythroleukemia. Zhonghua Xue Ye Xue Za Zhi 29:39–43
  12. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I et al (2008) Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease:a phase II study. Lancet 371:1579–1586
  13. Koc ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI et al (2000) Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 18:307–316
  14. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W et al (2002) Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30:42–48
  15. He J, Zhang Y, Jiang XX, Liu G, Liu YL, Li HL et al (2003) Effect of human bone marrow mesenchymal stem cell on cord blood T lymphocyte transformation. Zhongguo Shi Yan Xue Ye Xue Za Zhi 11:11–14
  16. Lee DH, Kang SK, Lee RH, Ryu JM, Park HY, Choi HS et al (2004) Effects of peripheral benzodiazepine receptor ligands on proliferation and differentiation of human mesenchymal stem cells. J Cell Physiol 198:91–99
  17. Devine SM, Cobbs C, Jennings M, Bartholomew A, Hoffman R (2003) Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 101:2999–3001
  18. Nagaya N, Fujii T, Iwase T, Ohgushi H, Itoh T, Uematsu M et al (2004) Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis. Am J Physiol Heart Circ Physiol 287:2670–2676
  19. Saito T, Kuang JQ, Bittira B, Al-Khaldi A, Chiu RC (2002) Xenotransplant cardiac chimera:immune tolerance of adult stem cells. Ann Thorac Surq 74:19–24
  20. Liechty KW, MacKenzie TC, Shaaban AF, Radu A, Moseley AM, Deans R et al (2000) Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med 6:1282–1286
  21. Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG et al (1993) Phenotypic characterization and identification of effecter cells involved in tumor cell recognition of cytokine induced killer cells. Exp Hematol 21:1673–1679
  22. Lu PH, Negrin RS (1994) A novel population of expanded human CD3?+?CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 153:1687–1696
  23. Carrancio S, Lopez-Holgado N, Sanchez-Guijo FM, Villarón E, Barbado V, Tabera S et al (2008) Optimization of mesenchymal stem cell expansion procedures by cell separation and culture conditions modification. Exp Hematol 36:1014–1021
  24. Thomas RJ, Chandra A, Liu Y, Hourd PC, Conway PP, Williams DJ (2007) Manufacture of a human mesenchymal stem cell population using an automated cell culture platform. Cytotechnology 55:31–39
  25. Li Y, Schmidt-Wolf IG, Wu YF, Huang SL, Wei J, Fang JP et al (2010) Optimized protocols for generation of cord blood derived cytokine-induced killer/natural killer cells. Anticancer Res 30:3493–3500
  26. Li Y, Zhang XC, Huang SL, Wei J, Huang WG, Zhou DH et al (2005) Establishment of an animal model of human erythroleukemia in NOD/SCID mice using microdose K562 cells. J Sun Yat sen University Medical Sci 26:523–527
  27. Tondreau T, Lagneaux L, Dejeneffe M, Massy M, Mortier C, Delforge A et al (2004) Bone marrow-derived mesenchymal stem cells already express specific neural proteins before any differentiation. Differentiation 72:319–326
  28. Lee AJ, Kim SG, Jeon CH, Suh HS, Yoon GS, Seo AN (2009) A case of natural killer cell leukemia misdiagnosed as tuberculous lymphadenopathy. Korean J Lab Med 29:194–198
  29. Siegel G, Schafer R, Dazzi F (2009) The immunosuppressive properties of mesenchymal stem cells. Transplantation 87:S45–S49
  30. Selmani Z, Naji A, Gaiffe E, Tiberghien P, Rouas-Freiss N, Carosella ED et al (2009) HLA-G is a crucial immunosuppressive molecule secreted by adult human mesenchymal stem cells. Transplantation 87:S62–S66
  31. Ramasamy R, Lam EW, Soeiro I et al (2007) Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells:impact on in vivo tumor growth. Leukemia 21:304–310
  32. Renner P, Eggenhofer E, Rosenauer A, Tisato V, Bonnet D, Dazzi F (2009) Mesenchymal stem cells require a sufficient,ongoing immune response to exert their immunosuppressive function. Transplant Proc 41:2607–2611
  33. Conget PA, Minguell JJ (1999) Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. J Cell Physiol 181:67–73
  34. Ren GW, Zhao X, Zhang LY, L'Huillier A, Ling W, Roberts AI et al (2010) Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol 184:2321–2328
  35. Mehta BA, Schmidt Wolf IG, Weissman IL, Negrin RS (1995) Two pathways of exo cytosis of cytoplasmic granule contents and targeT-cell killing by cytokine induced CD3?+?CD56+ killer cells. Blood 86:3493–3499
  36. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L (2006) Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107:1484–1490
  37. Skitzki J, Craig RA, Okuyama R, Knibbs RN, McDonagh K, Chang AE et al (2004) Donor cell cycling, trafficking, and accumulation during adoptive immunotherapy for murine lung metastases. Cancer Res 64:2183–2191
  38. Hazelrigg MR, Hirsch JI, Merchant RE (2002) Distribution of adoptivdy transferred, tumor-sensitized lymphocytes in the glioma-bearing rat. J Neurooncol 60:143–150
  39. Kim HM, Kang JS, Lim J, Kim JY, Kim YJ, Lee SJ et al (2009) Antitumor activity of cytokine-induced killer cells in nude mouse xenograft model. Arch Pharm Res 32:781–787
  40. Shields JD, Fleury ME, Yong C, Tomei AA, Randolph GJ, Swartz MA (2007) Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell 11:526–538
  41. T?gel F, Yang Y, Zhang P, Hu Z, Westenfelder C (2008) Bioluminescence imaging to monitor the in vivo distribution of administered mesenchymal stem cells in acute kidney injury. Am J Physiol Renal Physiol 295:315–321
  42. Horwitz EM, Keating A (2000) Nonhematopoietic mesenchymal stem cells: what are they? Cytotherapy 2:387–388
  43. Devine SM, Bartholomew AM, Mahmud N, Nelson M, Patil S, Hardy W, Sturgeon C et al (2001) Mesenchymal stem cells are capable of homing to the bone marrow of non-human promates following systemic infusion. Exp Hematol 29:244–255
  44. Zhou H, Ramiya VK, Visner GA (2006) Bone marrow stem cells as a vehicle for delivery of heme oxygenase-1 gene. Stem Cells Dev 15:79–86
  45. Huang K, Huang SL, Zhou DH, Cai Y, Zhang XC, Li Y (2007) Experiment study of efficacy on hematopoietic reconstitution and GVHD prophylaxis after mesenchymal cell infused by intra-bone marrow cavity or intravenous in rat BMT models. Zhonghua Xue Ye Xue Za Zhi 28:87–92
• 作者单位：http://www.springerlink.com/content/yr27171g84101378/
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Hematology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0584

文摘

Adoptive cellular immunotherapy is an important treatment to eliminate residual tumor cells after hematopoietic stem-cell transplantation. Bone marrow mesenchymal stem cells (MSC) have previously been shown to exert immunoregulation functions, including inhibition of proliferation and killing activities of T cells and natural killer (NK) cells in vitro and reduction of the graft-versus-host disease. MSC can survive in vivo for a long period of time, the influence of MSC on the antitumor activity of subsequently infused immune killer cells is not clear. The aim of this study was to investigate the influences of MSC infused via different paths and at different times on the antitumor activities of cytokine-induced killer (CIK)/NK cells derived from umbilical cord blood in K562 NOD/SCID mice. The potential interaction mechanisms of MSC and CIK/NK cells infused through different paths using different intervals in vivo were subsequently explored. The results show that the antitumor activities of CIK/NK cells was inhibited by MSC when injected via the same path (tail vein), and the suppressive effect of MSC on CIK/NK cells were less pronounced when they were injected separately through different paths. There were no effects of MSC on the antitumor activities of CIK/NK cells if the MSC and CIK/NK cells were injected with a 48-h interval. Moreover, the suppressive effect continuous, even if MSC were infused 48 h earlier than CIK/NK cells. It suggests that pre-injected MSC can reduce the antitumor activities of CIK/NK cells in vivo. The probable mechanisms are that MSC and CIK/NK cells might have a greater opportunity to meet and interact if they are injected simultaneously via the same path. The suppression of MSC on CIK/NK cells in vivo mainly takes place in the reticuloendothelial system, including the lung and the liver.